Topics
Glioblastoma | Treatment | Immunotherapy | Ipilimumab
Home > Publications > Topics > Glioblastoma > Treatment > Immunotherapy > Ipilimumab
2025
Neuro-Oncology Clinical Research Program; Camphausen K.
Phase
II Trial Evaluating the Association of Peripheral Blood
Immunologic Response to Therapeutic Response After Adjuvant
Treatment with Immune Checkpoint Inhibition (ICI) in Patients with
Newly Diagnosed Glioblastoma or Gliosarcoma.
medRxiv
[Preprint]. 2025 Dec 30:2025.12.23.25342908. doi:
10.64898/2025.12.23.25342908. PMID:
41607658. Trial
registration ID: NCT04817254. ˍ
2026
Sun L, Markus LF, Sanchez JC, Lai TJ, Lee EQ, Li G, Kim J, Zhuang
Z, Acevedo B, Everson RG, Mellinghoff IK, Aquilanti E, Nicolas
Gonzalez Castro L, Ricardo McFaline-Figueroa J, Nayak L, Beroukhim
R, Chong RA, Stone J, Kaley T, Schaff L, Wilcox J, Westergaard C,
Russ A, Lavallee M, Chukwueke U, Van den Abbeele AD, Lim M,
Ellingson BM, Reardon DA, Cloughesy TF, Prins RM, Wen PY.
Neoadjuvant PD1 plus CTLA-4 immune
checkpoint blockade in surgically resectable recurrent
glioblastoma: a randomized surgical window-of-opportunity trial.
Nat
Commun. 2026 Sep 5;17(1):10560. doi:
10.1038/s41467-026-77433-z. PMID:
42838943. Trial
registration ID: NCT04606316. ˍ